O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus

• Laura Geraldino-Pardilla,
• Subhashis Banerjee,
• Ann E Clarke,
• Eric Morand,
• Cristina Arriens,
• Ronald van Vollenhoven,
• Coburn Hobar,
• Samantha Pomponi,
• Ravi Koti,
• Thomas Wegman

Affiliations

Laura Geraldino-Pardilla

Division of Rheumatology, Department of Medicine, Columbia University College of Physicians & Surgeons, New York City, New York, USA

Subhashis Banerjee

7 Bristol Myers Squibb, Princeton, New Jersey, USA

Ann E Clarke

4Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Eric Morand

8School of Clinical Sciences, Monash University, Melbourne, VIC, Australia

Cristina Arriens

Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA

Ronald van Vollenhoven

Amsterdam University Medical Centers, Amsterdam, The Netherlands

Coburn Hobar

2Clinical Development, Bristol Myers Squibb, USA

Samantha Pomponi

6Bristol Myers Squibb, Princeton, NJ, USA

Ravi Koti

7Syneos Health, Morrisville, NC, USA

Thomas Wegman

6Bristol Myers Squibb, Princeton, NJ, USA